Quality-of-life outcomes with pimitespib in patients with advanced gastrointestinal stromal tumor: results from the randomized, double-blind, placebo-controlled, phase III, CHAPTER-GIST-301 study

20260 citationsJournal Articlegold Open Access

Authors

Y. Komatsu · Hokkaido University Hospital

N. Taira · Kawasaki Medical School

Y. Kurokawa · Osaka City University

Y. Honma · National Cancer Center Hospital East

A. Sawaki · Shonan Kamakura General Hospital

Y. Naito · National Cancer Center Hospital East

S. Iwagami ·

Abstract

Pimitespib as a new treatment option in the fourth-line setting did not negatively impact HRQoL overall, with the exception of diarrhea and appetite loss, in patients with metastatic GIST.

Topics & Keywords

Gastrointestinal Tumor Research and Treatment Gastric Cancer Management and Outcomes Intraperitoneal and Appendiceal Malignancies

UN Sustainable Development Goals

Zero hunger

Publication Details

Published in: ESMO Open

Volume 11, Issue 3, pp. 106088-106088

DOI: 10.1016/j.esmoop.2026.106088

Field-Weighted Citation Impact: 0.00